United Therapeutics (UTHR) Tops Q4 EPS Views; Guides FY13 Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Brean Downgrades United Therapeutics (UTHR) to Hold, Says Price Target Acheived
February 26, 2013 1:10 PM ESTBrean Capital downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Buy to Hold.
"We are downgrading United to Hold from Buy due to the achievement of our target price and our view that the next catalyst, a second FDA action on a refiled oral... More
